Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Express Scripts
Baxter
Boehringer Ingelheim
Harvard Business School

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for GDC-0152


Email this page to a colleague

« Back to Dashboard

What is the drug development status for GDC-0152?

GDC-0152 is an investigational drug.

There have been 183 clinical trials for GDC-0152. The most recent clinical trial was a Phase 3 trial, which was initiated on December 13th 2016.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.

There are sixty-five US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for GDC-0152
TitleSponsorPhase
Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT CarcinomaNational Cancer Institute (NCI)Phase 1/Phase 2
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSLKazia Therapeutics LimitedPhase 2
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSLLakshmi NayakPhase 2

See all GDC-0152 clinical trials

Clinical Trial Summary for GDC-0152

Top disease conditions for GDC-0152
Top clinical trial sponsors for GDC-0152

See all GDC-0152 clinical trials

US Patents for GDC-0152

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GDC-0152 ⤷  Try it Free Peptidomimetic macrocycles as modulators of MCL-1 AILERON THERAPEUTICS, INC. (Cambridge, MA) ⤷  Try it Free
GDC-0152 ⤷  Try it Free Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors AbbVie Inc. (North Chicago, IL) ⤷  Try it Free
GDC-0152 ⤷  Try it Free Bromodomain inhibitors AbbVie Inc. (North Chicago, IL) ⤷  Try it Free
GDC-0152 ⤷  Try it Free NAMPT and ROCK inhibitors AbbVie Inc. (North Chicago, IL) ⤷  Try it Free
GDC-0152 ⤷  Try it Free Bromodomain inhibitors AbbVie Inc. (North Chicago, IL) ⤷  Try it Free
GDC-0152 ⤷  Try it Free Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (La Jolla, CA) SALK INSTITUTE FOR BIOLOGICAL STUDIES (La Jolla, CA) ⤷  Try it Free
GDC-0152 ⤷  Try it Free Certain protein kinase inhibitor CHONGQING FOCHON PHARMACEUTICAL CO., LTD. (Chongqing, CN) SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (Shanghai, CN) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GDC-0152

Drugname Country Document Number Estimated Expiration Related US Patent
GDC-0152 China CN108368161 2035-09-10 ⤷  Try it Free
GDC-0152 European Patent Office EP3347372 2035-09-10 ⤷  Try it Free
GDC-0152 Japan JP2018528217 2035-09-10 ⤷  Try it Free
GDC-0152 World Intellectual Property Organization (WIPO) WO2017044633 2035-09-10 ⤷  Try it Free
GDC-0152 Argentina AR095266 2033-03-12 ⤷  Try it Free
GDC-0152 Australia AU2014231563 2033-03-12 ⤷  Try it Free
GDC-0152 Australia AU2018203833 2033-03-12 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Express Scripts
Baxter
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.